**Supplementary files**

Figure S1. Flow chart

**Assessed for eligibility**

(n=214)

**Excluded (n=69)**

BMI < 27kg/m2 Too mentally ill

(n=16) (n=2)

Declined to participate Unstable medication

(n=23) (n=9)

Severe somatic illness Substance Abuse

(n=12) (n=4)

Other schizophrenia-spectrum disorder

(n=3)

**Completed examinations**

(n=145)

**Prediabetes**

(n=101)

**Normal glucose tolerant (NGT)**

(n=44)

BMI denotes body mass index

Figure S2. GLP-1 and GIP during the 75-grams oral glucose tolerance test (n=10)



**A B**

**C D**

**A+B:** Total GLP-1. **C+D:**GIP. For the curves (A, C) values are means ± SEM**.** For the diagrams (B, D) tAUC and iAUC are presented as means ± SD. The participants were divided in the three groups: Sz-Prediabetes patients, Sz-NGT patients and healthy individuals. GLP-1 denotes glucagon-like peptide-1, GIP glucose-dependent insulinotropic peptide, tAUC and iAUC total and incremental area under the curve, Sz schizophrenia, NGT normal glucose tolerant, Controls healthy individuals, SEM standard error of the mean, SD standard deviation.